How to evaluate the results of a pharmacoeconomic study?;Come valutare i risultati di uno studio farmacoeconomico?

PharmacoEconomics - Italian Research Articles

Volumn 6, Issue 3, 2004, Pages 121-130

  Lucioni, Carlo ^a   Ravasio, R ^a  

^a Wolters Kluwer Health   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ARTICLE; AUSTRALIA; BIOTECHNOLOGY; BUDGET; CALCULATION; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; NATIONAL HEALTH SERVICE; PHARMACOECONOMICS; PUBLISHING; QUALITY OF LIFE; RESOURCE ALLOCATION; THEORY; UNITED KINGDOM; UNITED STATES;

EID: 4644359053     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320630     Document Type: Article

References (16)

1. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81
2. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-savings interventions and their cost-effectiveness. Risk Analysis 1995; (15) 3: 369-390
3. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). PharmacoEconomics 2001; 19 (11): 1103-9
4. NICE. NICE Present Evidence to Health Select Committee. London: NICE, 2002.
5. Towse A, Pritchard C. Does NICE have a threshold? An external view. In: Towse A, et al. (eds.). Cost-effectiveness threshold: economic and ethical issues. King's Fund and Office of Health Economics, November 2002
6. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452
7. Stafford M, Messori A, Trippoli S, et al. Problems in pharmacoeconomic analyses. JAMA 2000; 284: 1922-1924
8. Messori A, Santarlasci B, Trippoli S, et al. Controvalore economico del farmaco e beneficio clinico: stato dell'arte della metudologia e applicazione di un algoritmo farmacoeconomico. PharmacoEconomics - Italian Research Articles 2003; 5 (2): 53-67
9. Miller MA, McCann L. Policy analysis of Hepatitis B, Hemophilus influenzae type B, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedule. Health Econ 2000; 9: 19-35
10. Tyagi V, Snigh SK, Sawhney A, et al. Using Gross National Product to calculate acceptable immunisation costs. Deploying cost-effective calculations in reverse. PharmacoEconomics 2003; 21 (7): 497-499
11. Lindholm L, Hallgren C, Boman K, et al. Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease. Health Policy 1999; 48: 155-70
12. Lucioni C, Di Maio A, Ravasio R. II costo della salute in Europa. Prospettive Sociali c Sanitarie 2001; 21: 7-9
13. Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? PharmacoEconomics 2003; 21 (14): 991-1000
14. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37: 33-40
15. Chapman R, Stone P, Sandberg E, et al. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making 2000; 20: 451-67
16. Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. PharmacoEconomics 2003; 21 (3): 149-157